NCT02981316View on ClinicalTrials.gov

Treatment of Recurrent Clostridium Difficile Infection With RBX7455

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

November 30, 2016

Primary Completion Date

July 22, 2020

Study Completion Date

July 22, 2020

Conditions
Clostridium Difficile Infection
Interventions
BIOLOGICAL

RBX7455

Microbiota capsule(s) given twice daily in the morning, and in the evening.

Trial Locations (1)

55905

Mayo Clinic in Rochester, Rochester

Sponsors

Lead Sponsor

Mayo Clinic
All Listed Sponsors
collaborator

Rebiotix Inc.

INDUSTRY

lead

Mayo Clinic

OTHER